Printer Friendly

Existing Treatments For Hypertension Are Considered Safe And Effective, But A Significant Portion Of Patients Still Have Difficulty Controlling Their Blood Pressure.

DUBLIN, Ireland -- Research and Markets ( has announced the addition of "Renin Inhibitors, and poorly controlled hypertension can damage target organs, eventually resulting in heart failure, end-stage kidney disease, retinopathy, stroke, and vascular dementia.

The hypertension therapy market is also one of the largest markets in the world for prescription drugs. In this report, we examine a new class of antihypertensive drug, renin inhibitors. The first of these agents, aliskiren (Novartis/Speedel's Rasilez), is preregistered in the United States. If approved, it will be the first of a new class of antihypertensive drug to enter the market in more than a decade.

The hypertension market is large and mature; it comprises several drug classes, most of which are available in generic form, that compete for market share.

Renin inhibitors, which block the initial, rate-limiting step of the rennin angiotensinaldosterone system (RAAS), are a novel approach to hypertension treatment. The first agent in this class, aliskiren (Speedel/Novartis's Rasilez), is in preregistration. If approved, renin inhibitors will be the first novel drug class for hypertension treatment in more than a decade. Clinical trials have shown that aliskiren's efficacy in lowering BP is equal to that of many existing treatments. Aliskiren may also have potential as a combination therapy, enabling greater blockage of the RAAS and improved efficacy.

In addition, trials have shown that aliskiren does not elevate plasma renin activity, a benefit that suggests the drug may be less likely than existing treatments to cause end-organ damage. We anticipate that physicians will initially prescribe renin inhibitors as an alternative treatment as they attempt to find a drug or drug combination that will be well tolerated and enable patients to reach goal BPs.

Adoption will likely increase as more data emerge about renin inhibitors' side-effect profile and effect on end-organ damage. Because most rennin inhibitors, other than aliskiren, are still in early-stage development, aliskiren will enjoy a significant competitive advantage for several years as the only agent available.

Key Topics Covered Include:

- Introduction

- Overview of Hypertension

- Definition of Hypertension

- The Renin-Angiotensin-Aldosterone System

- Prevalence

- Current Treatment for Hypertension

- Current Therapies

- Unmet Needs in the Treatment of Hypertension

- Renin Inhibitors

- The Development of Renin Inhibitors

- Speedel/Novartis's Aliskiren

Companies Mentioned Include:

- Merck

- AstraZeneca

- Novartis

- Wyeth

- Bristol-Myers Squibb

- King Pharmaceuticals

- Sanofi-Aventis

- Novartis

- Biovail

- Watson Pharmaceuticals

- Forest

- Pfizer

- Abbott

- Speedel

- Actelion

- Vitae Pharmaceuticals

- GlaxoSmithKline

For more information visit
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 7, 2006
Previous Article:What Differentiates a Sports Drink from an Energy Drink? Find Out Inside This Report.
Next Article:How to contact nearly 2,000 Original Equipment Manufacturers (OEMs) - The Medical Device Register 2006.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters